Risk of malignant lymphoma in patients w
β
A.C.W. Vos; N. Bakkal; R.C. Minnee; M.K. Casparie; D.J. de Jong; G. Dijkstra; P.
π
Article
π
2011
π
John Wiley and Sons
π
English
β 319 KB
π 2 views
Background: Immune suppressant medications such as thiopurines and anti-tumor necrosis factor agents are important for maintaining disease control in most patients with inflammatory bowel diseases (IBDs); however, their use has been associated with the development of malignant lymphoma. The purpose